Abstract Session 11

Co-Chair(s)

• 

  Jesus Berdeja, MD (he/him/his)

  Director of Multiple Myeloma Research
  Tennessee Oncology
  Nashvile, Tennessee
• 

  Laura Rosinol, MD, PhD (she/her/hers)

  Amyloidosis and Myeloma Unit, Department of Hematology
  Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
  Barcelona, Catalonia, Spain

Presentations:

• 11:00 - 11:10 East Coast USA Time

  (OA-60) Updated Interim Results of Sonrotoclax + Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM): An All-Oral Treatment
  

  Abstract Presenter: Binod Dhakal, MD, MS – Medical College of Wisconsin
• 11:10 - 11:20 East Coast USA Time

  (OA-52) Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
  

  Abstract Presenter: Binod Dhakal, MD, MS – Medical College of Wisconsin
• 11:20 - 11:30 East Coast USA Time

  (OA-38) A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (Mm): Primary Analysis. Amarc 19-02 Belacard Study
  

  Abstract Presenter: Masa Lasica, MBBS, FRACP, FRCPA – St Vincent's Hospital Melbourne
• 11:30 - 11:40 East Coast USA Time

  (OA-56) Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
  

  Abstract Presenter: Hang Quach, MBBS(Hons) FRACP FRCPA MD (she/her/hers) – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
• 11:40 - 11:50 East Coast USA Time

  (OA-55) Treatment Patterns and Outcomes in Quad-Class Exposed (QCE) Relapsed Refractory Multiple Myeloma (RRMM): Investigating Critical Unmet Needs
  

  Abstract Presenter: Doris K. Hansen, MD – Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center